Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of pain with gap junction modulation compounds

A compound, interstitial technology, applied in the direction of drug combinations, chemical instruments and methods, non-central analgesics, etc., can solve the unmet problems of appropriate treatment options to improve outcomes and recovery

Inactive Publication Date: 2011-06-15
CODA THERAPEUTICS INC
View PDF74 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Despite advances in understanding the principles explaining the mechanisms involved in the causes of pain and pain relief, including pain associated with arthritic disease conditions and surgical and orthopedic procedures, there remains a lack of appropriate treatment options to improve outcome and recovery. unmet needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of pain with gap junction modulation compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0466] Formulations for transdermal delivery were prepared as follows.

[0467] First by dissolving the anti-connexin 43 oligonucleotide, SEQ ID NO.2 (Agilent, Boulder, CO) in PBS (Oxoid, UK BR0014 Dulbecco "A" tablet) to obtain a 500 micromolar stock solution. Prepare the anti-connexin 43 reagent solution.

[0468] Obtain emu oil from New Zealand commercial farm sources.

[0469] To prepare the formulation for application to the skin, heat emu oil to approximately 30°C and add 40 μl of the 50 μM stock solution to 960 μl of oil to prepare a 20 μM (20 μg per ml) formulation . The mixture was vortexed and stored at 4°C.

Embodiment 2

[0471] On the night before surgery, 55-year-old female subject A scheduled for knee replacement surgery applied 1 ml of the formulation described in Example 1 (containing 200 micrograms of SEQ ID NO: NO.2). The lap was wrapped in clingfilm overnight and the subject showered normally the next morning. The individual reported pain relief that lasted beyond the period of bed rest when the knee was moved while supporting the contralateral operated knee. After 7 days, some "rubbing" reappeared, but the pain relief lasted for about 10 days.

Embodiment 3

[0473] Subject A of Example 2 was subjected to a further treatment wherein 1 ml of the formulation described in Example 1 was applied to the calf skin of her operated leg 1 week after surgery for pain relief. The knee itself doesn't hurt because it's basically titanium and ceramic. However, she had pain above and below the surgical site, where the muscles and tendons were stretched to allow surgery. Following treatment, the individual reported significant and sustained pain relief in the treated area.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to delivery, including transdermal delivery, of a therapeutically effective amount of a compound useful for modulating gap junction formation and function, including an oligonucleotide for reducing gap junction formation and function, and methods and compositions for treating a subject suffering from pain associated with a disease, disorder or condition and associated with pain, including but not limited to muscle pain, ligament pain, tendon pain, joint pain and post-operative pain.

Description

field of invention [0001] The field of the invention relates to the delivery through the skin of compounds that relieve pain via modulation of gap junctions, including oligonucleotide gap junction modulators. Background of the invention [0002] The following contains information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art, or relevant to the presently described or claimed invention, or that any publication or document specifically or unqualifiedly cited is prior art. [0003] Pain has now become a common condition, a serious and costly public health problem, and a challenge to family, friends, and healthcare providers who must support individuals suffering from the physical and emotional consequences of pain. The International Association for the Study of Pain defines pain as "an unpleasant sensory and emotional experience associated with, or described with respect to, actual or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/11A61P25/00C12N15/113
CPCC12N15/1138C12N2310/11C12N2310/14C07K14/705A61P19/02A61P25/00A61P29/00
Inventor 布拉德福·J·杜甫特科林·格林
Owner CODA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products